OMEPRAZOLE EXTENDED-RELEASE CAPSULES

The Defense Logistics Agency awarded a delivery order under the basic indefinite-delivery contract SPE2DX-25-D-9900 to DMS PHARMACEUTICAL GROUP INC, identified by CAGE code 1UNB0, for 2 units of OMEPRAZOLE EXTENDED-RELEASE CAPSULES, NSN 6505016247068, at a total value of $101.60. The award was issued on July 1, 2026, with delivery scheduled for the same date, FOB destination at Kunsan Air Base, South Korea, where government personnel will inspect and accept the shipment. The contractor, designated as a small business, small disadvantaged business, and women-owned small business, is responsible for all transportation costs and risks until delivery. Payment will be processed by the Defense Finance and Accounting Service using voucher-based systems, with remittance directed to a Columbus, Ohio address and invoicing handled through the DLA Troop Support Medical Supply Chain in Philadelphia. The contract carries no variance allowance, with no options, extended performance periods, or additional line items, making it a single, fixed-quantity transaction. Administrative requirements include marking packages with contract identification numbers from Blocks 1 and 2, though no specific packaging, preservation, labeling standards, barcoding, or MIL-STD references are included. No formal contract clauses from FAR or DFARS are present in the delivery order itself, nor are there any special requirements, security clearances, personnel mandates, or OCI provisions specified. Representations related to socioeconomic status remain active and impose compliance obligations under applicable federal regulations. The procurement was conducted electronically through DIBBS, with no formal evaluation factors or technical specifications documented in the award notice, suggesting reliance on the underlying basic contract and established pharmaceutical supply standards for quality assurance.